Media headlines about Impax Laboratories (NASDAQ:IPXL) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Impax Laboratories earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 44.5271354777385 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Impax Laboratories (NASDAQ IPXL) traded down 3.26% during midday trading on Tuesday, hitting $19.30. The company had a trading volume of 13,006,590 shares. Impax Laboratories has a 52 week low of $7.75 and a 52 week high of $25.70. The stock’s market capitalization is $1.39 billion. The stock has a 50 day moving average price of $21.31 and a 200-day moving average price of $17.19.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.04. The business had revenue of $202.08 million for the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The company’s quarterly revenue was up 17.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.21 EPS. On average, equities analysts predict that Impax Laboratories will post $0.70 EPS for the current year.

Several brokerages have recently weighed in on IPXL. Canaccord Genuity set a $19.00 price target on Impax Laboratories and gave the company a “hold” rating in a report on Tuesday. Cantor Fitzgerald set a $25.00 price target on Impax Laboratories and gave the company a “buy” rating in a report on Tuesday. Zacks Investment Research upgraded Impax Laboratories from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a report on Monday. Goldman Sachs Group, Inc. (The) began coverage on Impax Laboratories in a report on Thursday, September 28th. They set a “neutral” rating and a $20.00 price target for the company. Finally, BTIG Research restated a “buy” rating and set a $27.00 price target (up from $20.00) on shares of Impax Laboratories in a report on Saturday, September 23rd. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have assigned a buy rating to the stock. Impax Laboratories presently has a consensus rating of “Hold” and a consensus target price of $18.92.

ILLEGAL ACTIVITY NOTICE: “Impax Laboratories (IPXL) Getting Somewhat Favorable Press Coverage, Study Finds” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Insider Buying and Selling by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.